NCT03575260已完成不适用
500mg Fulvestrant Versus Exemestane in Metastatic Breast Cancer (MBC) Resistant to Adjuvant Non-steroidal Aromatase Inhibitors in Clinical Practice- a Multicenter Retrospective Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
500mg Fulvestrant versus Exemestane in MBC
详细描述
500mg Fulvestrant versus Exemestane in Metastatic Breast Cancer (MBC) resistant to adjuvant Non-steroidal Aromatase Inhibitors in clinical practice- a multicenter retrospective study
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal woman, age > 18 years old
- •Diagnosed with ER/PR+，HER2- Metastatic Breast Cancer
- •Adjuvant treatment of Non-steroidal Aromatase Inhibitors
- •First line of Metastatic Breast Cancer is 500mg Fulvestrant or Exemestane for at least one month, starting from 2014.01.01-2017.06.01
- •Available medical history
排除标准
- •Incomplete medical history
结局指标
主要结局
PFS
时间窗: 6 weeks
Progression free survival
次要结局
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AIBreast CancerNCT03695341Fudan University130
Unknown
2 期
A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast CancerHR+/HER2-negative Breast CancerMetastasisBreast CancerNCT03560856Assistance Publique - Hôpitaux de Paris54
Unknown
不适用
Fulvestrant 500mg in Patients With Advanced Breast CancerMetastatic Breast CancerNCT02909361Fudan University500
Unknown
4 期
Fulvestrant in Metastatic Breast CancerMetastatic Breast CancerNCT03591549Assiut University30
尚未招募
不适用
It is a comparison between a combination of Bilastine with Montelukast and Fexofenadine with Montelukast in Allergic Rhinitis.CTRI/2022/11/047305ROHILKHAND MEDICAL COLLEGE AND HOSPITA